No Data
No Data
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Several Factors Lifted Repligen Corporation (RGEN) in Q3
Repligen Launches Novel AVIPure DsRNA Resin in OPUS Pre-packed Columns
RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating